▲ bullish
Impact
PhasePhase 3
Time to marketIf Phase 3 data is positive (expected 2H 2026), regulatory filing could follow in 2027, with potential FDA approval in 2028 at the earliest.
rinzimetostat Updated Aug 28
What to watch
Watch for rinzimetostat Phase 3 data readout expected in 2H 2026 (Himalayas-1 trial in mCRPC). Positive data would be a major catalyst for ORIC stock given rinzimetostat is the company's lead pipeline asset. The Bayer darolutamide collaboration strengthens the trial design without cost to ORIC.
Bull case
- Rinzimetostat is a potentially best-in-class dual EZH1/2 inhibitor advancing to a global Phase 3 registrational trial (Himalayas-1) in mCRPC, a large market opportunity.
- Strong analyst support: 10 Buy/2 Hold/0 Sell consensus with a mean price target of $20.67 (56.5% upside from ~$13.74).
- Cash runway into 2H 2028 ($387.6M) provides ample funding through Phase 3 readout without near-term financing risk.
Bear case
- Phase 3 clinical trials in oncology have a high failure rate (~50%+), and rinzimetostat's Himalayas-1 trial could fail to meet endpoints.
- The prostate cancer treatment landscape is highly competitive with established therapies (Xtandi, Zytiga, darolutamide) and emerging novel agents, making market entry difficult even with approval.
- ORIC is pre-revenue with no approved products; continued R&D spending ($36.3M in Q2 2026) and potential further ATM dilution are risks.